Literature DB >> 34102074

Graft Failure, Revision ACLR, and Reoperation Rates After ACLR With Quadriceps Tendon Versus Hamstring Tendon Autografts: A Registry Study With Review of 475 Patients.

Malte Schmücker1, Jørgen Haraszuk1, Per Hölmich1, Kristoffer W Barfod1.   

Abstract

BACKGROUND: It has been indicated that anterior cruciate ligament reconstruction (ACLR) with a quadriceps tendon (QT) graft has a higher risk of revision compared with ACLR performed with a hamstring tendon (HT) graft. PURPOSE/HYPOTHESIS: To investigate whether ACLR with QT graft had a higher risk of graft failure, revision ACLR, or reoperation compared with HT graft in a high-volume center. We hypothesized that there would be no between-group differences. STUDY
DESIGN: Cohort study; Level of evidence, 3.
METHODS: This was a registry study with review of medical records. Our study cohort consisted of patients who underwent primary ACLR with either QT or HT graft performed at Copenhagen University Hospital Hvidovre between January 2015 and December 2018. The cohort was identified from the Danish Knee Ligament Reconstruction Registry and linked to the Danish National Patient Registry to identify all hospital contacts after ACLR. The outcome variables were graft failure (rerupture or >3-mm side-to-side difference in anteroposterior [AP] laxity), revision ACLR, reoperation due to cyclops lesion, reoperation due to meniscal injury, and reoperation due to any reason. AP laxity and pivot shift were assessed at 1 year. Kaplan-Meier estimates were used to evaluate the rates of events at 2 years, and comparison was performed with Cox regression analysis.
RESULTS: A total of 475 patients (252 HT, 223 QT) were included. The rate of graft failure at 2 years was 9.4% for the QT group and 11.1% for the HT group (P = .46). For the QT and HT groups, respectively, the rate of revision ACLR was 2.3% and 1.6% (P = .60), the rate of reoperation due to cyclops lesion was 5.0% and 2.4% (P = .13), and the rate of reoperation due to meniscal injury was 4.3% and 7.1% (P = .16). The rate of reoperation due to any reason was 20.5% and 23.6% (P = .37). At 1-year follow-up, AP laxity was 1.4 mm for QT and 1.5 mm for HT (P = .51), and the proportion of patients with a positive pivot shift was 29-30% for both groups.
CONCLUSION: QT and HT grafts yielded similar rates of graft failure, revision ACLR, and reoperation at 2 years of follow-up after ACLR. Graft failure was found in 9% to 11% of patients. Patients with QT ACLR showed a non-statistically significant trend of higher risk for reoperation due to cyclops lesion, and those with HT showed a non-statistically significant trend of higher risk for reoperation due to meniscal injury.

Entities:  

Keywords:  ACL reconstruction; hamstring tendon; quadriceps tendon; revision

Year:  2021        PMID: 34102074     DOI: 10.1177/03635465211015172

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  3 in total

1.  Re-rupture rate and the post-surgical meniscal injury after anterior cruciate ligament reconstruction with the Press-Fit-Hybrid®-technique in comparison to the interference screw technique: a retrospective analysis of 200 patients with at least 3 years follow-up.

Authors:  Richard Volz; Gudrun H Borchert
Journal:  Arch Orthop Trauma Surg       Date:  2022-03-15       Impact factor: 3.067

Review 2.  Less than 1% risk of donor-site quadriceps tendon rupture post-ACL reconstruction with quadriceps tendon autograft: a systematic review.

Authors:  Harasees Singh; Isaac Glassman; Andrew Sheean; Yuichi Hoshino; Kanto Nagai; Darren de Sa
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-10-18       Impact factor: 4.114

3.  Correlation of Isokinetic Testing and ACL Failure With the Short Graft Tape Suspension Technique at Six Months.

Authors:  Mathieu Severyns; Stéphane Plawecki; Guillaume-Anthony Odri; Tanguy Vendeuvre; Frédéric Depiesse; Jean-Francois Flez; Louis-Antoine Liguori
Journal:  Arthrosc Sports Med Rehabil       Date:  2022-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.